Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: AurumRabosa who wrote (835)	3/29/2000 8:38:00 PM
From: Bosco	Read Replies (2) \| Respond to of 1298

Hi Ron - thanks for the NYT article. No, I don't know about the CEGE involvement, even though I vaguely know about the legal wrangling between TKT and AMGN. This is exciting in the sense that CEGE has nothing to lose but everything to gain. While I don't know about the legality of patenting, it seems to be in line with the recent political preference. So there is a good chance. Considering the stake, I don't think there is a quick outcome, especially if AMGN loses! best, Bosco

To: AurumRabosa who wrote (835)	3/30/2000 3:12:00 AM
From: tuck	Read Replies (1) \| Respond to of 1298

Hi, Ron, It's not the arbitrage that's attractive wrt CEGE by itself. It's the fact that a stake in a hot company can be moved quickly. CEGE is in position to sell shares of ABGX whenever a good opportunity -- such as this February's mo-mo spike -- arises. By contrast, a company like ABSC that can only sell it's own shares, must do so via a time consuming follow-on. ABSC thus missed this window and withdrew its follow-on. The ability to hedge CEGE against AMGN via the patent/royalty situation is icing on the cake. The cake itself is the fundamentals you mentioned, and the ABGX shares are the candles. Add match and . . . Bon Appetit! Tuck